BIOMAT Database Logo BIOMAT Database Logo

Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. 2022

Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Department of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, PR China; Institute of Materia Medica, Fujian Medical University (FMU), Fuzhou, PR China; Fujian Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University (FMU), Fuzhou, PR China.

Heat shock protein 90 (HSP90) is involved in the stabilization and activation of oncoproteins, rendering it essential for oncogenic transformation. However, the HSP90 inhibitors evaluated to date have not led to the expected effects in cancer therapy. Herein, we systematically described the design, synthesis, and evaluation of HSP90 degraders based upon the proteolysis-targeting chimera (PROTAC) strategy. The results showed that the candidate compound 16b (BP3) potently degraded HSP90 and effectively inhibited the growth of human breast cancer cells. When used as a single agent, BP3 led to effective tumor suppression in mice. These findings demonstrate that our HSP90-targeting PROTAC strategy has potential novel applications in breast cancer therapy.

UI MeSH Term Description Entries
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
October 2021, Bioorganic chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
October 2020, Journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
April 2021, European journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
July 2023, Journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
February 2019, Journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
October 2020, Acta pharmaceutica Sinica. B,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
September 2022, European journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
January 2019, Journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
August 2018, Journal of medicinal chemistry,
Quanyu Liu, and Guihui Tu, and Yan Hu, and Qingna Jiang, and Jingwen Liu, and Shanshan Lin, and Zelei Yu, and Ge Li, and Xinhua Wu, and Yuanling Tang, and Xiuwang Huang, and Jianhua Xu, and Yang Liu, and Lixian Wu
Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.
December 2021, European journal of medicinal chemistry,
Copied contents to your clipboard!